PL3364971T3 - Heterocykliczne inhibitory PDK1 do zastosowania w leczeniu nowotworu - Google Patents
Heterocykliczne inhibitory PDK1 do zastosowania w leczeniu nowotworuInfo
- Publication number
- PL3364971T3 PL3364971T3 PL16788389T PL16788389T PL3364971T3 PL 3364971 T3 PL3364971 T3 PL 3364971T3 PL 16788389 T PL16788389 T PL 16788389T PL 16788389 T PL16788389 T PL 16788389T PL 3364971 T3 PL3364971 T3 PL 3364971T3
- Authority
- PL
- Poland
- Prior art keywords
- heterocyclic
- treat cancer
- pdk1 inhibitors
- pdk1
- inhibitors
- Prior art date
Links
- 101100351314 Caenorhabditis elegans pdk-1 gene Proteins 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
- 125000000623 heterocyclic group Chemical group 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562245606P | 2015-10-23 | 2015-10-23 | |
| EP16788389.1A EP3364971B1 (en) | 2015-10-23 | 2016-10-21 | Heterocyclic pdk1 inhibitors for use to treat cancer |
| PCT/US2016/058255 WO2017070565A1 (en) | 2015-10-23 | 2016-10-21 | Heterocyclic pdk1 inhibitors for use to treat cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3364971T3 true PL3364971T3 (pl) | 2021-05-31 |
Family
ID=57209945
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL16788389T PL3364971T3 (pl) | 2015-10-23 | 2016-10-21 | Heterocykliczne inhibitory PDK1 do zastosowania w leczeniu nowotworu |
Country Status (14)
| Country | Link |
|---|---|
| US (3) | US20190015410A1 (pl) |
| EP (2) | EP3763368A1 (pl) |
| JP (1) | JP7094879B2 (pl) |
| KR (1) | KR20180101329A (pl) |
| CN (1) | CN108697699A (pl) |
| AU (2) | AU2016342352B2 (pl) |
| BR (1) | BR112018008025A2 (pl) |
| CA (1) | CA3002907A1 (pl) |
| DK (1) | DK3364971T3 (pl) |
| ES (1) | ES2820770T3 (pl) |
| MX (1) | MX381727B (pl) |
| PL (1) | PL3364971T3 (pl) |
| RU (1) | RU2018118786A (pl) |
| WO (1) | WO2017070565A1 (pl) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114763326A (zh) * | 2021-01-13 | 2022-07-19 | 南京宁丹新药技术有限公司 | 一类氨基酸酯衍生物及其用途 |
| BR112023021111A2 (pt) | 2021-04-13 | 2023-12-19 | Nuvalent Inc | Composto, composição farmacêutica, método de tratamento de câncer, método para inibir seletivamente her2, método de regulação de um nível de her2, método para aumentar um nível de her2, método de diminuição da fosforilação de her2 |
| WO2024040241A1 (en) | 2022-08-19 | 2024-02-22 | Viracta Therapeutics, Inc. | Pharmaceutical formulations, processes for preparation, and methods of use |
| WO2024040242A1 (en) * | 2022-08-19 | 2024-02-22 | Viracta Therapeutics, Inc. | Combinations of pdk1 inhibitors and kinase inhibitors |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4911920A (en) | 1986-07-30 | 1990-03-27 | Alcon Laboratories, Inc. | Sustained release, comfort formulation for glaucoma therapy |
| FR2588189B1 (fr) | 1985-10-03 | 1988-12-02 | Merck Sharp & Dohme | Composition pharmaceutique de type a transition de phase liquide-gel |
| JP2594486B2 (ja) | 1991-01-15 | 1997-03-26 | アルコン ラボラトリーズ インコーポレイテッド | 局所的眼薬組成物 |
| US5212162A (en) | 1991-03-27 | 1993-05-18 | Alcon Laboratories, Inc. | Use of combinations gelling polysaccharides and finely divided drug carrier substrates in topical ophthalmic compositions |
| US6309853B1 (en) | 1994-08-17 | 2001-10-30 | The Rockfeller University | Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof |
| DE102005061655A1 (de) * | 2005-12-22 | 2007-06-28 | Merck Patent Gmbh | Diazepinone |
| CN102665718B (zh) * | 2009-10-06 | 2016-03-09 | 米伦纽姆医药公司 | 可用作pdk1抑制剂的杂环化合物 |
| EP2507244B1 (en) * | 2009-12-04 | 2014-11-05 | Nerviano Medical Sciences S.r.l. | Tricyclopyrazole derivatives |
| WO2019094779A1 (en) * | 2017-11-09 | 2019-05-16 | Sunesis Pharmaceuticals, Inc. | Pharmaceutical formulations, processes for preparation, and methods of use |
-
2016
- 2016-10-21 CN CN201680072623.7A patent/CN108697699A/zh active Pending
- 2016-10-21 PL PL16788389T patent/PL3364971T3/pl unknown
- 2016-10-21 MX MX2018004977A patent/MX381727B/es unknown
- 2016-10-21 AU AU2016342352A patent/AU2016342352B2/en not_active Ceased
- 2016-10-21 CA CA3002907A patent/CA3002907A1/en active Pending
- 2016-10-21 RU RU2018118786A patent/RU2018118786A/ru unknown
- 2016-10-21 EP EP20180303.8A patent/EP3763368A1/en not_active Withdrawn
- 2016-10-21 KR KR1020187014416A patent/KR20180101329A/ko not_active Ceased
- 2016-10-21 DK DK16788389.1T patent/DK3364971T3/da active
- 2016-10-21 JP JP2018520428A patent/JP7094879B2/ja active Active
- 2016-10-21 EP EP16788389.1A patent/EP3364971B1/en active Active
- 2016-10-21 US US15/770,369 patent/US20190015410A1/en not_active Abandoned
- 2016-10-21 ES ES16788389T patent/ES2820770T3/es active Active
- 2016-10-21 BR BR112018008025-0A patent/BR112018008025A2/pt not_active Application Discontinuation
- 2016-10-21 WO PCT/US2016/058255 patent/WO2017070565A1/en not_active Ceased
-
2022
- 2022-05-12 AU AU2022203204A patent/AU2022203204A1/en not_active Abandoned
- 2022-06-02 US US17/831,041 patent/US20230099829A1/en not_active Abandoned
-
2024
- 2024-03-11 US US18/600,974 patent/US20240207258A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP3364971B1 (en) | 2020-06-17 |
| AU2016342352B2 (en) | 2022-06-02 |
| RU2018118786A3 (pl) | 2020-02-25 |
| EP3364971A1 (en) | 2018-08-29 |
| US20190015410A1 (en) | 2019-01-17 |
| EP3763368A1 (en) | 2021-01-13 |
| MX381727B (es) | 2025-03-13 |
| AU2016342352A1 (en) | 2018-05-10 |
| MX2018004977A (es) | 2018-07-06 |
| BR112018008025A2 (pt) | 2018-10-23 |
| US20230099829A1 (en) | 2023-03-30 |
| KR20180101329A (ko) | 2018-09-12 |
| ES2820770T3 (es) | 2021-04-22 |
| AU2022203204A1 (en) | 2022-06-02 |
| RU2018118786A (ru) | 2019-11-26 |
| US20240207258A1 (en) | 2024-06-27 |
| CA3002907A1 (en) | 2017-04-27 |
| CN108697699A (zh) | 2018-10-23 |
| JP7094879B2 (ja) | 2022-07-04 |
| WO2017070565A1 (en) | 2017-04-27 |
| DK3364971T3 (da) | 2020-09-21 |
| JP2018538244A (ja) | 2018-12-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL272905A (en) | Methods of treating pancreatic cancer | |
| IL251669A0 (en) | Cancer treatment using a tlr9 agonist with checkpoint inhibitors | |
| IL243976A0 (en) | kdm1a inhibitors for disease treatment | |
| IL241232A0 (en) | Cancer treatment agents | |
| SMT202200250T1 (it) | Composti eterociclici come inibitori della pi3k-gamma | |
| EP2968348A4 (en) | COMPOUNDS FOR THE TREATMENT OF CANCER | |
| IL285077A (en) | Compounds for the treatment of cancer | |
| IL278247B (en) | mct4 inhibitors to treat the disease | |
| IL251778B (en) | Novel pyrazolopyrimidine histories as nik inhibitors | |
| SI3164394T1 (sl) | GLS1 inhibitorji za zdravljenje bolezni | |
| IL244353A0 (en) | Compounds and use for cancer treatment | |
| IL244118B (en) | A preparation containing dexpermipexole for the treatment of various types of urticaria | |
| ZA201701450B (en) | Small molecule inhibitors for cancer therapy | |
| EP2986317A4 (en) | INHIBITION OF RIP KINASES FOR THE TREATMENT OF LYSOSOMAL STORAGE DISEASES | |
| EP3152195A4 (en) | Mth1 inhibitors for treatment of cancer | |
| SG11201508878WA (en) | Methods of treating cancer | |
| IL240688A0 (en) | Pancreatic cancer treatment methods | |
| IL249674A0 (en) | Quinolizinone derivatives as inhibitors of pi3k | |
| GB201420533D0 (en) | Use of Nanomaterials in treating cancer | |
| EP2961403A4 (en) | HETEROCYCLIC INHIBITORS OF SODIUM CHANNEL | |
| IL259781A (en) | Uses of pyrimido-pyridazinones to treat cancer | |
| PL3364971T3 (pl) | Heterocykliczne inhibitory PDK1 do zastosowania w leczeniu nowotworu | |
| ZA201507762B (en) | Methods of treating cancer | |
| TWI561255B (en) | Use of umirolimus and its derivatives for treating cancer | |
| ZA201403006B (en) | Composition for use in treatment of cancer |